Drug-drug interactions between antiseizure medications and antipsychotic medications: a narrative review and expert opinion

References

• Josephson CB, Jetté N. Psychiatric comorbidities in epilepsy. Int Rev Psychiatry. 2017;29(5):409–424. doi: 10.1080/09540261.2017.1302412
   PubMed Web of Science ®Google Scholar
• Tellez-Zenteno JF, Patten SB, Jetté N, et al. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia. 2007;48(12):2336–2344. doi: 10.1111/j.1528-1167.2007.01222.x
   PubMed Web of Science ®Google Scholar
• Gaitatzis A, Trimble MR, Sander JW. The psychiatric comorbidity of epilepsy. Acta Neurol Scand. 2004;110(4):207–220. doi: 10.1111/j.1600-0404.2004.00324.x
   PubMed Web of Science ®Google Scholar
• Devinsky O. Psychiatric comorbidity in patients with epilepsy: implications for diagnosis and treatment. Epilepsy Behav. 2003;4:2–10. doi: 10.1016/j.yebeh.2003.10.002
   PubMed Web of Science ®Google Scholar
• Kaufman KR. Antiepileptic drugs in the treatment of psychiatric disorders. Epilepsy Behav. 2011;21(1):1–11. doi: 10.1016/j.yebeh.2011.03.011
   PubMed Web of Science ®Google Scholar
• Ettinger AB, Argoff CE. Use of antiepileptic drugs for nonepileptic conditions: psychiatric disorders and chronic pain. Neurotherapeutics. 2007;4(1):75–83. doi: 10.1016/j.nurt.2006.10.003
   PubMed Web of Science ®Google Scholar
• Johannessen Landmark C, Larsson PG, Rytter E, et al. Antiepileptic drugs in epilepsy and other disorders—A population-based study of prescriptions. Epilepsy Res. 2009;87(1):31–39. doi: 10.1016/j.eplepsyres.2009.07.005
   PubMed Web of Science ®Google Scholar
• Landmark CJ. Antiepileptic drugs in non-epilepsy disorders. CNS Drugs. 2008;22(1):27–47. doi: 10.2165/00023210-200822010-00003
   PubMed Web of Science ®Google Scholar
• Olfson M, King M, Schoenbaum M. Treatment of young people with antipsychotic medications in the United States. JAMA Psychiatry. 2015;72(9):867–874. doi: 10.1001/jamapsychiatry.2015.0500
   PubMed Web of Science ®Google Scholar
• Olfson M, Blanco C, Liu S-M, et al. National trends in the Office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry. 2012;69(12):1247–1256. doi: 10.1001/archgenpsychiatry.2012.647
   PubMed Web of Science ®Google Scholar
• Besag FMC. Epilepsy in patients with autism: links, risks and treatment challenges. Neuropsychiatr Dis Treat. 2018;14:1–10. doi: 10.2147/NDT.S120509
   PubMed Web of Science ®Google Scholar
• Chen B, Choi H, Hirsch LJ, et al. Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy. Epilepsy Behav. 2017;76:24–31. doi: 10.1016/j.yebeh.2017.08.039
   PubMed Web of Science ®Google Scholar
• Mula M, Sander JW. Negative Effects of Antiepileptic Drugs on Mood in Patients with Epilepsy. Drug Saf. 2007;30(7):555–567. doi: 10.2165/00002018-200730070-00001
   PubMed Web of Science ®Google Scholar
• Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet Neurol. 2012;11(9):792–802. doi: 10.1016/S1474-4422(12)70153-9
   PubMed Web of Science ®Google Scholar
• Weintraub D, Buchsbaum R, Resor SR, et al. Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy. Epilepsy Behav. 2007;10(1):105–110. doi: 10.1016/j.yebeh.2006.08.008
   PubMed Web of Science ®Google Scholar
• Hedges D, Jeppson K, Whitehead P. Antipsychotic medication and seizures: a review. Drugs Today (Barc). 2003 Jul;39(7):551–557. PubMed PMID: 12973403; eng. doi: 10.1358/dot.2003.39.7.799445.
   PubMed Web of Science ®Google Scholar
• Pisani F, Oteri G, Costa C, et al. Effects of psychotropic drugs on seizure threshold. Drug Saf. 2002;25(2):91–110. doi: 10.2165/00002018-200225020-00004
   PubMed Web of Science ®Google Scholar
• Spina E, Pisani F, De Leon J. Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics. Pharmacol Res. 2016 Apr 1;106:72–86. PubMed PMID: 1771645243; 608560066; Eng. doi: 10.1016/j.phrs.2016.02.014
   PubMed Web of Science ®Google Scholar
• (NICE) NIfHaCE. British National Formulary (BNF). 2023 [cited 2023 May 31]. Available from: https://bnf.nice.org.uk/
   Google Scholar
• Kennedy WK, Jann MW, Kutscher EC. Clinically significant drug interactions with atypical antipsychotics. CNS Drugs. 2013 Dec;27(12):1021–1048. PubMed PMID: 1447063387; 24170642; eng. doi: 10.1007/s40263-013-0114-6
   PubMed Web of Science ®Google Scholar
• De Leon J, Santoro V, D’Arrigo C, et al. Interactions between antiepileptics and second-generation antipsychotics. Expert Opin Drug Metab Toxicol. 2012 Mar;8(3):311–334. PubMed PMID: 923882563; 364300426; Eng. doi: 10.1517/17425255.2012.660918
   PubMed Web of Science ®Google Scholar
• Besag FMC, Berry D. Interactions between antiepileptic and antipsychotic drugs. Drug Saf. 2006;29(2):95–118. PubMed PMID: 698898048; 43213885; Eng. doi: 10.2165/00002018-200629020-00001
   PubMed Web of Science ®Google Scholar
• Patsalos PN. Psychotropic drugs. Antiseizure medication interactions: a clinical guide. Cham: Springer International Publishing; 2022. p. 319–335.
   Google Scholar
• Patsalos PN, Fröscher W, Pisani F, et al. The importance of drug interactions in epilepsy therapy. Epilepsia. 2002 Apr;43(4):365–385. PubMed PMID: 11952767; eng. doi: 10.1046/j.1528-1157.2002.13001.x
   PubMed Web of Science ®Google Scholar
• Winans E. Aripiprazole. Am J Health Sys Pharma. 2003 Dec 1;60(23):2437–2445. PubMed PMID: 14686220; eng. doi: 10.1093/ajhp/60.23.2437
   PubMed Web of Science ®Google Scholar
• Citrome L, Macher J-P, Salazar DE, et al. Pharmacokinetics of Aripiprazole and Concomitant Carbamazepine. J Clin Psychopharmacol. 2007;27(3):279–283. PubMed PMID: 00004714-200706000-00008. doi: 10.1097/jcp.0b013e318056f309
   PubMed Web of Science ®Google Scholar
• Nakamura A, Mihara K, Nagai G, et al. Pharmacokinetic and pharmacodynamic interactions between carbamazepine and aripiprazole in patients with schizophrenia. Ther Drug Monit. 2009;31(5):575–578. PubMed PMID: 00007691-200910000-00007. doi: 10.1097/FTD.0b013e3181b6326a
   PubMed Web of Science ®Google Scholar
• Castberg I, Spigset O. Effects of comedication on the serum levels of aripiprazole: evidence from a routine therapeutic drug monitoring service. Pharmacopsychiatry. 2007;40(3):107–110. En. doi: 10.1055/s-2007-977715
   PubMed Web of Science ®Google Scholar
• Taylor D. Pharmacokinetic interactions involving clozapine. Br J Psychiatry. 1997 Aug;171:109–112. PubMed PMID: 9337943; eng. doi: 10.1192/bjp.171.2.109
   PubMed Web of Science ®Google Scholar
• Fang J, Coutts RT, McKenna KF, et al. Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine. Naunyn Schmiedebergs Arch Pharmacol. 1998 Nov;358(5):592–599. PubMed PMID: 9840430; eng. doi: 10.1007/pl00005298
   PubMed Web of Science ®Google Scholar
• Raitasuo V, Lehtovaara R, Huttunen MO. Carbamazepine and plasma levels of clozapine. Am J Psychiatry. 1993;150:169–169. doi: 10.1176/ajp.150.1.169a
   PubMed Web of Science ®Google Scholar
• Raitasuo V, Lehtovaara R, Huttunen MO. Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics. A case report. Psychopharmacology. 1994;116(1):115–116. doi: 10.1007/BF02244881
   PubMed Web of Science ®Google Scholar
• Jerling M, Lindström L, Bondesson U, et al. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit. 1994 Aug;16(4):368–374. PubMed PMID: 7974626; eng. doi: 10.1097/00007691-199408000-00006
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Vartiainen H, Hakola P. Carbamazepine-induced changes in plasma levels of neuroleptics. Pharmacopsychiatry. 1995 Jan;28(1):26–28. PubMed PMID: 7746842; eng. doi: 10.1055/s-2007-979584
   PubMed Web of Science ®Google Scholar
• Kudo S, Ishizaki T. Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet. 1999 Dec;37(6):435–456. PubMed PMID: 10628896; eng. doi: 10.2165/00003088-199937060-00001
   PubMed Web of Science ®Google Scholar
• Jann MW, Ereshefsky L, Saklad SR, et al. Effects of carbamazepine on plasma haloperidol levels. J Clin Psychopharmacol. 1985;5(2):106–109. PubMed PMID: 00004714-198504000-00010. doi: 10.1097/00004714-198504000-00010
   PubMed Web of Science ®Google Scholar
• Arana GW, Goff DC, Friedman H, et al. Does carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms? Am J Psychiatry. 1986 May;143(5):650–651. PubMed PMID: 3963258; eng. doi: 10.1176/ajp.143.5.650
   PubMed Web of Science ®Google Scholar
• Kahn EM, Schulz SC, Perel JM, et al. Change in haloperidol level due to carbamazepine–a complicating factor in combined medication for schizophrenia. J Clin Psychopharmacol. 1990 Feb;10(1):54–57. PubMed PMID: 2106534; eng. doi: 10.1097/00004714-199002000-00011
   PubMed Web of Science ®Google Scholar
• Iwahashi K, Miyatake R, Suwaki H, et al. The drug-drug interaction effects of haloperidol on plasma carbamazepine levels. Clin Neuropharmacol. 1995 Jun;18(3):233–236. PubMed PMID: 8635181; eng. doi: 10.1097/00002826-199506000-00003
   PubMed Web of Science ®Google Scholar
• Hesslinger B, Normann C, Langosch JM, et al. Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. J Clin Psychopharmacol. 1999;19(4):310–315. PubMed PMID: 00004714-199908000-00005. doi: 10.1097/00004714-199908000-00005
   PubMed Web of Science ®Google Scholar
• Martín Muñoz JC, Moriñigo Domínguez AV, Mateo Martín I, et al. Carbamazepine: an effective adjuvant treatment in the schizophrenias. Actas Luso Esp Neurol Psiquiatr Cienc Afines. 1989 Jul;17(4):245–250. PubMed PMID: 2678932; spa.
   PubMedGoogle Scholar
• Hirokane G, Someya T, Takahashi S, et al. Interindividual variation of plasma haloperidol concentrations and the impact of concomitant medications: the analysis of therapeutic drug monitoring data. Ther Drug Monit. 1999 Feb;21(1):82–86. PubMed PMID: 10051058; eng. doi: 10.1097/00007691-199902000-00012
   PubMed Web of Science ®Google Scholar
• Yukawa E, Hokazono T, Funakoshi A, et al. Epidemiologic investigation of the relative clearance of haloperidol by mixed-effect modeling using routine clinical pharmacokinetic data in Japanese patients. J Clin Psychopharmacol. 2000 Dec;20(6):685–690. PubMed PMID: 11106142; eng. doi: 10.1097/00004714-200012000-00016
   PubMed Web of Science ®Google Scholar
• Fukuda R. Factors affecting serum haloperidol level assessed by longitudinal therapeutic monitoring. Prog Neuropsychopharmacol Biol Psychiatry. 2000 Nov;24(8):1299–1318. PubMed PMID: 11125855; eng. doi: 10.1016/s0278-5846(00)00142-1
   PubMed Web of Science ®Google Scholar
• Yasui-Furukori N, Kondo T, Mihara K, et al. Significant dose effect of carbamazepine on reduction of steady-state plasma concentration of haloperidol in schizophrenic patients. J Clin Psychopharmacol. 2003 Oct;23(5):435–440. PubMed PMID: 14520118; eng. doi: 10.1097/01.jcp.0000088902.24613.63
   PubMed Web of Science ®Google Scholar
• Callaghan JT, Bergstrom RF, Ptak LR, et al. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999 Sep;37(3):177–193. PubMed PMID: 10511917; eng. doi: 10.2165/00003088-199937030-00001
   PubMed Web of Science ®Google Scholar
• Linnet K. Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes. Hum Psychopharmacol. 2002 Jul;17(5):233–238. PubMed PMID: 12404680; eng. doi: 10.1002/hup.403
   PubMed Web of Science ®Google Scholar
• Skogh E, Reis M, Dahl ML, et al. Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting. Ther Drug Monit. 2002 Aug;24(4):518–526. PubMed PMID: 12142637; eng. doi: 10.1097/00007691-200208000-00010
   PubMed Web of Science ®Google Scholar
• Botts S, Diaz FJ, Santoro V, et al. Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model. Prog Neuro Psychopharmacol Biol Psychiatry. 2008;32(6):1453–1458. doi: 10.1016/j.pnpbp.2008.04.018
   PubMed Web of Science ®Google Scholar
• Olesen OV, Linnet K. Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication. Ther Drug Monit. 1999;21(1):87–90. PubMed PMID: 00007691-199902000-00013. doi: 10.1097/00007691-199902000-00013
   PubMed Web of Science ®Google Scholar
• Linnet K, Olesen OV. Free and glucuronidated olanzapine serum concentrations in psychiatric patients: influence of carbamazepine comedication. Ther Drug Monit. 2002;24(4):512–517. PubMed PMID: 00007691-200208000-00009. doi: 10.1097/00007691-200208000-00009
   PubMed Web of Science ®Google Scholar
• Gex-Fabry M, Balant-Gorgia AE, Balant LP. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit. 2003;25(1):46–53. PubMed PMID: 00007691-200302000-00007. doi: 10.1097/00007691-200302000-00007
   PubMed Web of Science ®Google Scholar
• de Leon J, Wynn G, Sandson NB. The pharmacokinetics of paliperidone versus risperidone. Psychosomatics. 2010;51(1):80–88. doi: 10.1016/S0033-3182(10)70664-2
   PubMed Web of Science ®Google Scholar
• Dolder C, Nelson M, Deyo Z. Paliperidone for schizophrenia. Am J Health Syst Pharm. 2008;65(5):403–413. doi: 10.2146/ajhp070261
   PubMed Web of Science ®Google Scholar
• Helland A, Spigset O. Serum concentrations of paliperidone after administration of the long-acting injectable formulation. Ther Drug Monit. 2017 Dec;39(6):659–662. PubMed PMID: 1952088924; 29040230; eng. doi: 10.1097/FTD.0000000000000457.
   PubMed Web of Science ®Google Scholar
• Kerbusch-Herben V, Cleton A, Berwaerts J, et al. Effect of carbamazepine on the pharmacokinetics of paliperidone extended-release tablets at steady-state. Clin Pharmacol Drug Dev. 2014 Sep;3(5):371–377. PubMed PMID: 1785607319; 27129010; eng. doi: 10.1002/cpdd.122
   PubMed Web of Science ®Google Scholar
• DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet. 2001;40(7):509–522. PubMed PMID: 11510628; eng. doi: 10.2165/00003088-200140070-00003
   PubMed Web of Science ®Google Scholar
• Castberg I, Skogvoll E, Spigset O. Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service. J Clin Psychiatry. 2007 Oct;68(10):1540–1545. PubMed PMID: 17960969; eng. doi: 10.4088/jcp.v68n1011
   PubMed Web of Science ®Google Scholar
• Santoro V, D’Arrigo C, Migliardi G, et al. Therapeutic drug monitoring of quetiapine: effect of coadministration with antiepileptic drugs in patients with psychiatric disorders. Open Clin Chem J. 2008;1(1):17–21.
   Google Scholar
• Wittmann M, Hausner H, Köstlbacher A, et al. Individual clearance and therapeutic drug monitoring of quetiapine in clinical practice. Neuro Endocrinol Lett. 2010;31(2):203–207. PubMed PMID: 20424588; eng.
   PubMed Web of Science ®Google Scholar
• Hasselstrøm J, Linnet K. Quetiapine serum concentrations in psychiatric patients: the influence of comedication. Ther Drug Monit. 2004;26(5):486–491. PubMed PMID: 00007691-200410000-00005. doi: 10.1097/00007691-200410000-00005
   PubMed Web of Science ®Google Scholar
• Kopecek M, Potmesil P. How long does the pharmacokinetic interaction between carbamazepine and quetiapine last after carbamazepine withdrawal? Neuro Endocrinol Lett. 2017 Dec;38(7):475–478. PubMed PMID: 29369597; eng.
   PubMed Web of Science ®Google Scholar
• Schoretsanitis G, Haen E, Gründer G, et al. Pharmacokinetic drug-drug interactions of Mood stabilizers and risperidone in patients under combined treatment. J Clin Psychopharmacol. 2016 Dec;36(6):554–561. PubMed PMID: 1836075586; 27811552; eng. doi: 10.1097/JCP.0000000000000601
   PubMed Web of Science ®Google Scholar
• Spina E, Avenoso A, Facciolà G, et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate. Ther Drug Monit. 2000;22(4):481–485. PubMed PMID: 00007691-200008000-00019. doi: 10.1097/00007691-200008000-00019
   PubMed Web of Science ®Google Scholar
• Ono S, Mihara K, Suzuki A, et al. Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes. Psychopharmacol (Berl). 2002 Jun;162(1):50–54. PubMed PMID: 12107617; eng. doi: 10.1007/s00213-002-1056-8
   PubMed Web of Science ®Google Scholar
• Spina E, Perucca E. Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. Epilepsia. 2002;43(s2):37–44. doi: 10.1046/j.1528-1157.2002.043s2037.x
   PubMedGoogle Scholar
• Yuen AW, Land G, Weatherley BC, et al. Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol. 1992 May;33(5):511–513. PubMed PMID: 1524964; PubMed Central PMCID: PMCPMC1381438. eng. doi: 10.1111/j.1365-2125.1992.tb04079.x
   PubMed Web of Science ®Google Scholar
• Benedetti MS. Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fundam Clin Pharmacol. 2000 Jul;14(4):301–319. PubMed PMID: 11030437; eng. doi: 10.1111/j.1472-8206.2000.tb00411.x
   PubMed Web of Science ®Google Scholar
• Waade RB, Christensen H, Rudberg I, et al. Influence of Comedication on Serum Concentrations of Aripiprazole and Dehydroaripiprazole. Ther Drug Monit. 2009;31(2):233–238. PubMed PMID: 00007691-200904000-00012. doi: 10.1097/FTD.0b013e3181956726
   PubMed Web of Science ®Google Scholar
• Andersson ML, Björkhem-Bergman L, Lindh JD. Possible drug–drug interaction between quetiapine and lamotrigine – evidence from a Swedish TDM database. Br J Clin Pharmacol. 2011;72(1):153–156. doi: 10.1111/j.1365-2125.2011.03941.x
   PubMed Web of Science ®Google Scholar
• Spina E, D’Arrigo C, Migliardi G, et al. Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. Ther Drug Monit. 2006;28(5):599–602. PubMed PMID: 00007691-200610000-00005. doi: 10.1097/01.ftd.0000246763.59506.b0
   PubMed Web of Science ®Google Scholar
• Martin H, Sarsat JP, de Waziers I, et al. Induction of cytochrome P450 2B6 and 3A4 expression by phenobarbital and cyclophosphamide in cultured human liver slices. Pharm Res. 2003 Apr;20(4):557–568. PubMed PMID: 12739762; eng. doi: 10.1023/a:1023234429596
   PubMed Web of Science ®Google Scholar
• Gerbal-Chaloin S, Pascussi JM, Pichard-Garcia L, et al. Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos. 2001 Mar;29(3):242–251. PubMed PMID: 11181490; eng.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Someya T, Shimoda K, et al. Importance of the cytochrome P450 2D6 genotype for the drug metabolic interaction between chlorpromazine and haloperidol. Ther Drug Monit. 2001 Aug;23(4):363–368. PubMed PMID: 11477317; eng. doi: 10.1097/00007691-200108000-00007
   PubMed Web of Science ®Google Scholar
• Loga S, Curry S, Lader M. Interactions of orphenadrine and phenobarbitone with chlorpromazine: plasma concentrations and effects in man. Br J Clin Pharmacol. 1975;2(3):197–208. doi: 10.1111/j.1365-2125.1975.tb01576.x
   PubMed Web of Science ®Google Scholar
• Facciolà G, Avenoso A, Spina E, et al. Inducing effect of phenobarbital on clozapine metabolism in patients with chronic schizophrenia. Ther Drug Monit. 1998;20(6):628–630. PubMed PMID: 00007691-199812000-00008. doi: 10.1097/00007691-199812000-00008
   PubMed Web of Science ®Google Scholar
• Linnoila M, Viukari M, Vaisanen K, et al. Effect of anticonvulsants on plasma haloperidol and thioridazine levels. Am J Psychiatry. 1980;137(7):819–821. PubMed PMID: 6770696; eng. doi: 10.1176/ajp.137.7.819
   PubMed Web of Science ®Google Scholar
• Yukawa E, Hokazono T, Yukawa M, et al. Population pharmacokinetics of haloperidol using routine clinical pharmacokinetic data in Japanese patients. Clin Pharmacokinet. 2002;41(2):153–159. PubMed PMID: 11888334; eng. doi: 10.2165/00003088-200241020-00006
   PubMed Web of Science ®Google Scholar
• Wójcikowski J, Maurel P, Daniel WA. Characterization of human cytochrome P450 enzymes involved in the metabolism of the piperidine-type phenothiazine neuroleptic thioridazine. Drug Metab Dispos. 2006;34(3):471–476. doi: 10.1124/dmd.105.006445
   PubMed Web of Science ®Google Scholar
• Thorn CF, Whirl-Carrillo M, Leeder JS, et al. PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466–470. PubMed PMID: 22569204; PubMed Central PMCID: PMCPMC3349446. eng. doi: 10.1097/FPC.0b013e32834aeedb
   PubMed Web of Science ®Google Scholar
• Wong YW, Yeh C, Thyrum PT. The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine. J Clin Psychopharmacol. 2001 Feb;21(1):89–93. PubMed PMID: 11199955; eng. doi: 10.1097/00004714-200102000-00016
   PubMed Web of Science ®Google Scholar
• Patsalos PN. The mechanism of action of topiramate. Rev Contemp Pharmaco. 1999;10(3):147–153.
   Google Scholar
• Nallani SC, Glauser TA, Hariparsad N, et al. Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate. Epilepsia. 2003 Dec;44(12):1521–1528. PubMed PMID: 14636322; eng. doi: 10.1111/j.0013-9580.2003.06203.x
   PubMed Web of Science ®Google Scholar
• Vieta E, Sánchez-Moreno J, Goikolea JM, et al. Effects on weight and outcome of long-term olanzapine-topiramate combination treatment in bipolar disorder. J Clin Psychopharmacol. 2004 Aug;24(4):374–378. PubMed PMID: 15232327; eng. doi: 10.1097/01.jcp.0000130556.01373.45
   PubMed Web of Science ®Google Scholar
• Bialer M, Doose DR, Murthy B, et al. Pharmacokinetic interactions of topiramate. Clin Pharmacokinet. 2004;43(12):763–780. PubMed PMID: 15355124; eng. doi: 10.2165/00003088-200443120-00001
   PubMed Web of Science ®Google Scholar
• Ghodke-Puranik Y, Thorn CF, Lamba JK, et al. Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet Genom. 2013;23(4):236–241. PubMed PMID: 01213011-201304000-00008. doi: 10.1097/FPC.0b013e32835ea0b2
   PubMed Web of Science ®Google Scholar
• Citrome L, Josiassen R, Bark N, et al. Pharmacokinetics of Aripiprazole and Concomitant Lithium and Valproate. J Clin Pharmacol. 2005;45(1):89–93. doi: 10.1177/0091270004269870
   PubMed Web of Science ®Google Scholar
• Gerrits MGF, de Greef R, Dogterom P, et al. Valproate reduces the glucuronidation of asenapine without affecting asenapine plasma concentrations. J Clin Pharmacol. 2012;52(5):757–765. doi: 10.1177/0091270011404028
   PubMed Web of Science ®Google Scholar
• Centorrino F, Baldessarini RJ, Kando J, et al. Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. Am J Psychiatry. 1994 Jan;151(1):123–125. PubMed PMID: 8267110; eng. doi: 10.1176/ajp.151.1.123
   PubMed Web of Science ®Google Scholar
• Centorrino F, Baldessarini RJ, Kando JC, et al. Clozapine and metabolites: concentrations in serum and clinical findings during treatment of chronically psychotic patients. J Clin Psychopharmacol. 1994;14:119–125. doi: 10.1097/00004714-199404000-00006
   PubMed Web of Science ®Google Scholar
• Wong J-Y, Leung S-P, Mak T, et al. Plasma clozapine levels and clinical response in treatment-refractory Chinese schizophrenic patients. Progress In Neuro-Psychopharmacology And Biological Psychiatry. 2006;30(2):251–264.
   PubMed Web of Science ®Google Scholar
• Diaz FJ, Santoro V, Spina E, et al. Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. Pharmacopsychiatry. 2008 May;41(3):81–91. PubMed PMID: 18484549; eng. doi: 10.1055/s-2007-1004591
   PubMed Web of Science ®Google Scholar
• Riesselman A, Strobl B, Cooley AT, et al. A case report that suggested that Aspirin’s effects on valproic acid metabolism May contribute to valproic acid’s inducer effects on clozapine metabolism. J Clin Psychopharmacol. 2013;33(6):812–814. PubMed PMID: 00004714-201312000-00016. doi: 10.1097/JCP.0b013e3182a4ea8f
   PubMed Web of Science ®Google Scholar
• Diaz FJ, Eap CB, Ansermot N, et al. Can valproic acid be an inducer of clozapine metabolism? Pharmacopsychiatry. 2014 May;47(3):89–96. PubMed PMID: 24764199; PubMed Central PMCID: PMCPMC4229130. eng. doi: 10.1055/s-0034-1371866
   PubMed Web of Science ®Google Scholar
• Facciolà G, Avenoso A, Scordo MG, et al. Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders. Ther Drug Monit. 1999;21(3):341. PubMed PMID: 00007691-199906000-00017. doi: 10.1097/00007691-199906000-00017
   PubMed Web of Science ®Google Scholar
• Smith RL, Wollmann BM, Kyllesø L, et al. Effect of valproic acid on the metabolic spectrum of clozapine in patients with schizophrenia. J Clin Psychopharmacol. 2022;42(1):43–50. PubMed PMID: 2618312842; 2016330513; Eng. doi: 10.1097/JCP.0000000000001507
   PubMed Web of Science ®Google Scholar
• Sangüesa E, Cirujeda C, Concha J, et al. Pharmacokinetic interactions between clozapine and valproic acid in patients with treatment-resistant schizophrenia: does UGT polymorphism affect these drug interactions? Chem Biol Interact. 2022 Sep 1;364. doi:10.1016/j.cbi.2022.110042. PubMed PMID: 2695096155; 2019349580; Eng.
   PubMed Web of Science ®Google Scholar
• Bergemann N, Kress KR, Abu-Tair F, et al. Valproate lowers plasma concentration of olanzapine. J Clin Psychopharmacol. 2006;26(4):432–434.
   PubMed Web of Science ®Google Scholar
• Spina E, D’Arrigo C, Santoro V, et al. Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder. Ther Drug Monit. 2009;31(6):758–763. PubMed PMID: 00007691-200912000-00015. doi: 10.1097/FTD.0b013e3181c0590e
   PubMed Web of Science ®Google Scholar
• de Leon J, Diaz FJ, Spina E. Pharmacokinetic drug-drug interactions between olanzapine and valproate need to be better studied. J Clin Psychiatry. 2010 Jul;71(7):957–958. author reply 958-9 PubMed PMID: 20667295; eng. doi: 10.4088/JCP.09lr05902yel
   PubMed Web of Science ®Google Scholar
• Gonzalez-Heydrich J, Raches D, Wilens TE, et al. Retrospective study of hepatic enzyme elevations in children treated with olanzapine, divalproex, and their combination. J Am Acad Child Adolesc Psychiatry. 2003 Oct;42(10):1227–1233. PubMed PMID: 14560173; eng. doi: 10.1097/00004583-200310000-00014
   PubMed Web of Science ®Google Scholar
• Freeman MP, Stoll AL. Mood stabilizer combinations: a review of safety and efficacy. Am J Psychiatry. 1998 Jan;155(1):12–21. PubMed PMID: 9433333; eng. doi: 10.1176/ajp.155.1.12
   PubMed Web of Science ®Google Scholar
• Remmerie B, Ariyawansa J, De Meulder M, et al. Drug-drug interaction studies of paliperidone and divalproex sodium extended-release tablets in healthy participants and patients with psychiatric disorders. J Clin Pharmacol. 2016 Jun;56(6):683–692. PubMed PMID: 1717375831; 26412032; eng. doi: 10.1002/jcph.648
   PubMed Web of Science ®Google Scholar
• Aichhorn W, Marksteiner J, Walch T, et al. Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations. Int Clin Psychopharmacol. 2006;21(2):81–85. PubMed PMID: 00004850-200603000-00002. doi: 10.1097/01.yic.0000188213.46667.f1
   PubMed Web of Science ®Google Scholar
• Winter HR, DeVane CL, Figueroa C, et al. Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder. Hum Psychopharmacol Clin Exp. 2007;22(7):469–476.
   PubMed Web of Science ®Google Scholar
• Haidukewych D, Rodin EA. Effect of phenothiazines on serum antiepileptic drug concentrations in psychiatric patients with seizure disorder. Ther Drug Monit. 1985;7(4):401–404. PubMed PMID: 4082239; eng. doi: 10.1097/00007691-198512000-00006
   PubMed Web of Science ®Google Scholar
• Ishizaki T, Chiba K, Saito M, et al. The effects of neuroleptics (haloperidol and chlorpromazine) on the pharmacokinetics of valproic acid in schizophrenic patients. J Clin Psychopharmacol. 1984 Oct;4(5):254–261. PubMed PMID: 6149238; eng. doi: 10.1097/00004714-198410000-00004
   PubMed Web of Science ®Google Scholar
• Jann MW, Hon YY, Shamsi SA, et al. Lack of pharmacokinetic interaction between lamotrigine and olanzapine in healthy volunteers. Pharmacother J Human Pharmacol Drug Ther. 2006;26(5):627–633. doi: 10.1592/phco.26.5.627
   Google Scholar
• Reimers A, Skogvoll E, Sund JK, et al. Drug interactions between lamotrigine and psychoactive drugs: evidence from a therapeutic drug monitoring service. J Clin Psychopharmacol. 2005 Aug;25(4):342–348. PubMed PMID: 702192493; 41060254; Eng. doi: 10.1097/01.jcp.0000169418.31275.a7
   PubMed Web of Science ®Google Scholar
• Sidhu J, Job S, Bullman J, et al. Pharmacokinetics and tolerability of lamotrigine and olanzapine coadministered to healthy subjects. Br J Clin Pharmacol. 2006;61(4):420–426.
   PubMed Web of Science ®Google Scholar
• Mula M, Monaco F. Carbamazepine-risperidone interactions in patients with epilepsy. Clin Neuropharmacol. 2002 Mar;25(2):97–100. PubMed PMID: 11981236; eng. doi: 10.1097/00002826-200203000-00007
   PubMed Web of Science ®Google Scholar
• Zaccara G, Bartolini E, Tramacere L, et al. Drugs for patients with epilepsy and excessive daytime sleepiness. Epilepsy Behav. 2021;124.
   Google Scholar
• Fang F, Sun H, Wang Z, et al. Antipsychotic drug-induced somnolence: incidence, mechanisms, and management. CNS Drugs. 2016;30(9):845–867. doi: 10.1007/s40263-016-0352-5
   PubMed Web of Science ®Google Scholar
• Mintzer S, Skidmore CT, Abidin CJ, et al. Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein. Ann Neurol. 2009;65(4):448–456. doi: 10.1002/ana.21615
   PubMed Web of Science ®Google Scholar
• Indiana University School of Medicine. Drug interactions Flockhart table. [cited 2023 Aug 17]. Available from: https://drug-interactions.medicine.iu.edu/MainTable.aspx
   Google Scholar
• PSIAC. [cited 2023 Aug 17]. Available from: https://www.psiac.de/
   Google Scholar
• Medscape UK. Drug Interactions Checker [cited 2023 Aug 17]. Available from: https://www.medscape.co.uk/drug-interaction-checker
   Google Scholar
• mediQ. [cited 2023 Aug 17]. Available from: https://www.mediq.ch/
   Google Scholar
• British National Formulary (BNF). Interactions A - Z. [cited 2023 Aug 17]. Available from: https://bnf.nice.org.uk/interactions/
   Google Scholar
• Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018 Jan 01;51(1–2):9–62. PubMed PMID: 1943593363; 618457357; Eng. doi: 10.1055/s-0043-116492
   PubMed Web of Science ®Google Scholar
• Schoretsanitis G, Paulzen M, Unterecker S, et al. TDM in psychiatry and neurology: a comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians. World J Biol Psychiatry. 2018 Apr;19(3):162–174. PubMed PMID: 29493375; eng. doi: 10.1080/15622975.2018.1439595
   PubMed Web of Science ®Google Scholar